137 results about "Intestines mucosa" patented technology

The invention relates to unique compositions containing enriched and purified natural crocin and/or crocetin for prevention and/or treatment of cancers and other conditions and diseases. Compositions comprise mainly enriched or purified natural crocin or crocetin or combination of both and possible other active phytochemicals. A composition is used as functional food, drink, dietary supplement, or therapeutic dosage to a human orally or through other appropriate way (parenteral, percutaneous, rectal, mucosal, intranasal or topical administration). A method of natural crocin and crocetin enriching and purification is revealed.

The invention specifically relates to a bifidobacterium microcapsule and a preparing method thereof. The bifidobacterium is obligatorily anaerobic and very sensitive to oxygen, PH, temperature, humidity, and other adverse external environment, thereby being very hard to remain activity during production, storage and transport; besides, if taken orally in a form of dry bifidobacterium powder, the bifidobacterium cannot tolerate low-pH value gastric acid, bile salt, and other environments, so a purpose that massive survived bifidobacteria arrive at an intestinal tract and colonise on the intestinal mucosa is hard to be guaranteed. The preparing method disclosed by the invention comprises the following steps of: adding freeze-dried bifidobacterium powder into a sodium alginate solution and then mixing in soybean oil, emulsifying the mixed solution and standing; centrifugally collecting micro-capsules; and drying the micro-capsules by using a vacuum freeze-drying technology. The bifidobacterium microcapsule disclosed by the invention has the advantages of gastric acid resistance, bile salt resistance and entericsolubility, high survival rate of bifidobacterium, simple preparation method, strong practicality, convenience for industrial production, and excellent storage stability and solves the problem of short storage period of probiotics preparations.

The invention belongs to a nutritive food production field, concretely an intestinal mucosa protection and restoration type enteral nutritive product and a preparation technology thereof, and provides a product capable of protecting intestinal mucosa, promoting restoration of the intestinal mucosa after injury, preventing and mitigating patient constipation, and providing equalization nutrition support. The nutritive product is prepared from micromolecule peptides of sea animals, glutamine dipeptide, soybean peptide, maltodextrin, dietary fiber, and medium- and long-chain triacylglycerol oil, etc., is blended with composite vitamins, prebiotics and probiotics according to nitrogen and heat requirements recommended to medium stress patients, can protect the intestinal mucosa and promote restoration of the intestinal mucosa, and promotes intestinal colonization of beneficial bacteria, thereby inhibiting harmful bacteria proliferation, reducing endotoxin generation, preventing movement of endotoxin, and providing a nitrogen source, carbohydrate, fat and vitamins required by a human body in a pathologic period. The product is suitable for a patient with intestinal mucosa injury caused by a plurality of factors like wound, great surgery operation and tumour chemotherapy, is safe and has no toxic side effect, and can be prepared to be electuary or functional nutritive injectable suspension.

The invention provides a method for preparing an intestine nutritive peptide by using wheat, and belongs to the technical field of deep processing of wheat protein. The method comprises the following steps: (1) pre-mixing the wheat with polysaccharide and adding water for dispersion, so that wheat protein suspension liquid solubilized through the polysaccharide is obtained; (2) selecting protamex<TM> to perform restriction enzymolysis on the wheat protein step by step, wherein the substrate obtained in the later step is a precipitate produced through enzymolysis in the step (1), the times for enzymolysis are controlled to be 3-4, and when the protein content in the final precipitate is less than 5% (dry basis), the enzymolysis is stopped; (3) using a continuous enzymolysis-membrane separation coupling system for treating a supernatant centrifuged through enzymolysis in the above steps, adding a certain amount of alcalase in the system for enzymolysis for a certain time, and then desalting permeating liquid through nanofiltration, so that wheat oligopeptide with high glutamine is obtained. The wheat active peptide prepared through the method can alleviate injury degree of enteritis rat intestinal mucosa, and promote the synthesis of intestinal mucosa protein and DNA, and has an obvious efficacy of enteral nutrition.

The invention relates to the technical field of the production of heparin sodium, and provides a process for extracting heparin sodium efficiently from small intestines of pigs. According to the process, casings and intestinal mucosae are combined to prepare the heparin sodium, so that the utilization rate of the small intestines of the pigs is improved, the additional value of the small intestines of the pigs is increased, 0.1 billion international units of heparin sodium crude products are extracted only from about 1,400 small intestines of the pigs, the purity of the product is high, and the valence of the heparin sodium is more than 100 U/mg. Simultaneously, the residual casings can also be utilized effectively. Trypsin enzyme liquid is prepared from fresh porcine pancreas serving as raw materials and is used for extracting the heparin sodium, so that artificially-synthetic substances are reduced greatly, and the naturalness of the product is improved; and the heparin sodium is extracted from the trypsin enzyme liquid, so that peculiar smell generated in the production process can be reduced to the maximum degree, and environmental protection is facilitated.

The invention relates to the technical field of production of heparin sodium and provides a process for extracting heparin sodium from an intestinal mucosa by an alkaline protease method. The process mainly comprises the steps of performing enzymolysis, adsorbing, washing, eluting, precipitating and drying. According to the process, the production cycle is short, the products have high yield and purity, discharge of intestinal residue and waste water is reduced, and environmental protection is promoted. 100 million international units of heparin sodium crude products can be produced only by about 1,600 small intestines of pigs, and the valence of the heparin sodium is more than 110 U/mg.

The invention discloses application of lactobacillus reuteri in preventing and relieving ulcerative colitis, and belongs to the technical field of functional microorganisms. Lactobacillus reuteri CCFM1135 can tolerate the gastrointestinal environment of a human body, significantly reduce the disease activity index during the ulcerative colitis, improve colon mucosal injury, reduce MPO activity, reduce the content of proinflammatory factors TNF-alpha, IL-6 and IFN-gamma in colon, up-regulate the transcription level of colon tight junction related proteins Claudin-3, ZO-1, ZO-2 and Occludin, up-regulate the transcription levels of colon antibacterial peptides Reg3g and Reg3b, improve the diversity of intestinal flora, and reduced the relative abundance of acinetobacter in excrement.

The invention discloses a lactobacillus plantarum for relieving ulcerative colitis and application thereof, and belongs to the technical field of functional microorganisms. The lactobacillus plantarum CCFM1117 can tolerate the gastrointestinal environment of a human body, reduce weight loss in the ulcerative colitis disease period, improve fecal characters and hemafecia conditions, relieve length shortening of the colon, improve colonic mucosal injury, reduce the content of proinflammatory factors TNF-alpha, IL-1beta, IL-6 and IFN-gamma in the colon, up-regulate the gene transcription level of colon tight junction related proteins Claudin-3, ZO-1, ZO-2 and Occludin, increase the content of short-chain fatty acid, increase the abundance of short-chain fatty acid producing bacteria Coprococcus and butyric acid producing bacteria Faecalibacterium, and improve the diversity of intestinal flora.

The invention relates to the technical field of heparin sodium production, and provides a technology for extracting high-purity heparin sodium from intestinal mucosa by a trypsin method. The technology is characterized by adopting a fresh pig pancreas as the raw material to prepare a trypsin liquid and to extract the heparin sodium, therefore, utilization of artificial compositions is reduced greatly, the product nature is improved, the yield is high, and only about 1600 pig small intestines are needed to produce hundred million international units of the crude heparin sodium product; furthermore, as the trypsin liquid is adopted to extract the heparin sodium, peculiar smell in a production process can be reduced to a large extent, and the environmental protection is facilitated. According to the invention, a re-dissolution and re-precipitation step is added, so that the problem that the product purity is lower due to the fact that salt crystal is formed easily by a high-concentration alcohol and an eluent and is mixed in the heparin sodium product. The purity of the heparin sodium product processed by the technology is improved remarkably, and the titer of the heparin sodium is larger than 130 U/mg.

The invention discloses an application of lactobacillus rhamnosus to preventing and relieving ulcerative colitis, and belongs to the technical field of functional microorganisms. The lactobacillus rhamnosus can tolerate the gastrointestinal environment of a human body, significantly reduce weight loss during the period of ulcerative colitis, improve fecal traits and hematochezia, improve colon mucosal injury, reduce MPO activity, and reduce the content of proinflammatory factors TNF-alpha, IL-1beta, IL-6 and IFN-gamma in colon. The transcription levels of colon close junction related proteins Claudin-3, ZO-1, ZO-2 and Occludin, antibacterial peptides Reg3g and Reg3b and mucoprotein MUC2 are up-regulated, the abundance of short-chain fatty acid producing bacteria Coprococcus and Faecalibacterium and the content of short-chain fatty acid are improved, the abundance of beneficial bacteria Lactobacillus in intestinal tracts is increased, the abundance of the conditional pathogenic bacteria Acinetobacter is reduced, and the abundance and diversity of intestinal flora are increased.

The invention is based on the identification of aminopeptidase N (APN) as the receptor for F4 fimbriae of enterotoxigenic E. coli (ETEC). Based on the observation that oral administration of F4 fimbriae induces a protective intestinal mucosal immune response against a subsequent challenge with F4 ETEC, and the observation that the internalization of said F4 fimbriae is clathrin-mediated, the present invention provides the characterization of APN as a target useful in: in an in vitro assay to screen for molecules that are capable to mimic the clathrin-mediated F4 endocytosis; in an in vitro assay to screen for molecules that are capable to modulate the binding of F4 fimbriae with APN; in the development of a carrier for the delivery of antigens/therapeutics, i.e. immunomodulators to the intestinal submucosa or the intestinal mucosa-associated lymphoid tissue, wherein said carrier comprises an APN specific target molecule that mimics the clathrin-mediated F4 endocytosis. The use of the carriers thus identified or the treatments thus identified, in a method of inducing an antigen specific intestinal mucosal immune response, and/or in the treatment of bacterial diarrhea, is a further aspect of the present invention.

The invention provides bifidobacterium longum subsp. Longum KLDS K5 capable of preventing and relieving symptoms of colitis, and belongs to the technical field of microorganisms. The invention further provides a preparation method of the bifidobacterium longum subsp. Longum KLDS K5. Experiments show that the bifidobacterium longum provided by the invention can tolerate the human gastrointestinal environment, relieve weight loss in the ulcerative colitis disease period, improve colonic mucosa injury and reduce MPO activity, and inhibit oxidation-related factors through iNOS and COX-2 signal pathways so as to relieve inflammatory bowel diseases; nF-kappa B p65 nuclear transfer is inhibited through a TLR4/MyD88/NF-kappa B signal channel, the expression quantity of proinflammatory factors TNF-alpha, IL-1beta, IL-6 and IL-10 in colon is reduced, the transcriptional level of colon tight connection related proteins Claudin-1, ZO-1 and Occludin and mucoprotein MUC2 is up-regulated, the intestinal flora change after DSS induction can be improved in the genus level, and the richness and diversity of the intestinal flora are improved.

The invention provides a dairy product capable of improving type 2 diabetes mellitus or regulating intestinal flora. The dairy product contains bifidobacterium lactis MN-Gup. The dairy product provided by the invention can improve the characteristic intestinal flora of the type 2 diabetes mellitus in a targeted manner, and regulate the diversity of the intestinal flora and/or the balance of the intestinal flora; the dairy product can improve the type 2 diabetes mellitus through a comprehensive mechanism, including significant relieving of weight loss and islet injury, blood sugar level reduction, intestinal mucosa repairing, intestinal insulin improvement, in-vivo inflammation state improvement and healthy intestinal flora recovery.

The invention relates to a preparation and purification method for biological medicinal raw material, belonging to the field of bioengineering, and in particular relates to a technology for preparing high purity low molecular heparin sodium. The method aims at overcoming the defects of the prior art. The invention provides a convenient technology for preparing and purifying low molecular heparin sodium. The average molecular mass of the prepared low molecular heparin sodium is about 4.5KDa, the titer of the prepared low molecular heparin sodium is not lower than 180U/mg and is higher than 170U/mg required in Chinese pharmacopoeia, and the prepared low molecular heparin sodium is up to standard according to the test standard of the heparin sodium in the Chinese pharmacopoeia.

The invention belongs to the technical field, and particularly relates to application of bifidobacterium MN-Gup and a microbial inoculum thereof in treating type 2 diabetes mellitus. The invention provides bifidobacterium lactis MN-Gup or a microbial inoculum with a main component of bifidobacterium lactis MN-Gup, which can improve type 2 diabetes mellitus through a comprehensive mechanism, such as relieving islet injury, repairing intestinal mucosa, improving related inflammatory response, improving expression of intestinal insulin GLP-1, recovering intestinal flora health and the like. The problem that at present, a probiotic for specifically adjusting type 2 diabetes related intestinal flora and recovering healthy intestinal flora to improve, relieve or treat type 2 diabetes is lacked is solved.

The invention relates to the technical field of microorganisms, and discloses a compound bacterium agent. The compound bacterium agent is prepared from at least two of bifidobacterium longum, lactobacillus paracasei and lactobacillus plantarum. Compared with a model control group, through the compound bacterium agent, the rat gastric mucosa bleeding belt area can be significantly decreased, the gastric mucosa blood flow is increased, and the gastric mucosa damage index is decreased. The mouse colon length is significantly increased, the mouse colon tissue pathology score is decreased, and ulcerative colitis caused by intestinal mucosa damage of mice is relieved. Therefore, the probiotics compound bacterium agent has a certain gastric and intestinal mucosa protection effect, and is very suitable for preparation of food, health care products, medicines and food supplements.

The invention discloses a heparin sodium extraction method. The heparin sodium extraction method is characterized in that the method solves problems of insufficient intestinal mucosa enzymatic hydrolysis and bad adsorption effect of traditional enzymatic hydrolysis technologies. A non-uniform enzymatic hydrolysis phenomenon is generated in the traditional enzymatic hydrolysis technologies. The method enables full enzymatic hydrolysis to be carried out through introducing different supersonic waves in different enzymatic hydrolysis phases, so the content of heparin sodium in the obtained enzymatic hydrolysis liquid is improved, and the heparin sodium is fully released. The method enables an adsorption mother liquid to be purified through filtering in an adsorption phase, so the adsorption environment is clean, the adsorption of the resin is easy, and pollution and obstruction are less, thereby the production efficiency of the heparin sodium is improved. The heparin sodium yield is improved by 10-20% through the above two steps, so the method has a substantial economic benefit.

The invention provides probiotic. The probiotic comprises a bacteria strip and a light fluid, wherein the bacteria strip comprises prebiotics, a strawberry fruit powder, lactobacillus plantarum LP45,bifidobacterium lactis BAL531, lactobacillus acidophilus La28, lactobacillus paracasei YMC1069, lactobacillus rhamnosus LR519, bifidobacterium bifidum TMC3115, lactobacillus reuteri L840, lactobacillus gasseri L838 and bifidobacterium animalis subsp. Lactis B420; and the light fluid comprises skimmed milk powder, maltodextrin, whey protein concentrate powder, fruit powder, konjaku flour, coconut powder, a sugar substitute, a freeze-dried fruit granule, chia seed, psyllium husk and compound vitamins. The invention also provides a method for improving the survival rate and planting rate of the probiotic in the intestinal tract. According to the method, a manner of first taking the light fluid on an empty stomach and then mixing the light fluid with the bacteria strip and then taking the mixture is adopted, the light fluid which is first taken neutralizes gastric acid and bile salt, then the bacteria strip is fully fused with the light fluid, and then a flora of the probiotic is successfully planted in the intestinal mucosa.

The invention relates to application of lactobacillus rhamnosus to preparation of food or medicine for preventing and/or treating ulcerative colitis. The lactobacillus rhamnosus with the effect of relieving the ulcerative colitis is named as lactobacillus rhamnosus LRa05 strain, the preservation unit is China General Microbiological Culture Collection Center, the preservation time is July 20, 2020, the preservation number is CGMCC No.1. 12734, and the address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The lactobacillus rhamnosus LRa05 strain can be used for remarkably relieving the ulcerative colitis and remarkably improving the colonic mucosa inflammation lesion, and the lactobacillus rhamnosus LRa05 strain has a good prospect when being used for preparing the food or the medicine for preventing and/or treating the ulcerative colitis or the colonic mucosa inflammation.

The invention relates to a traditional Chinese medicine composite as well as a product and an application of the traditional Chinese medicine composite. The composite comprises the following traditional Chinese medicine raw materials in parts by weight: 20-40 parts of Astragalus mongholicus and 10-20 parts of mulberry and also comprises one or several of the following traditional Chinese medicine raw materials in parts by weight: 5-15 parts of salviae miltiorrhizae, 5-15 parts of angelica sinensis, 10-20 parts of processed fleece-flower root, 5-15 parts of rhizoma chuanxiong and 1-5 parts of pseudo-ginseng. The traditional Chinese medicine composite has better actions on lowering sugar, lowering fat, improving a blood rheology index, reducing urine protein or improving the creatinine clearance rate and especially has the actions on protecting the vascular endothelial cell, alleviating the damage degree of the endarterium and the like, and therefore the traditional Chinese medicine composite can be prepared into oral administration or external application products used for treating or controlling renal damage, neuropathy around limbs, high blood fat, impotence, prostatic hyperplasia, diabetes mellitus and complications, such as diabetic foot, diabetic nephropathy and diabetic retinal inflammation, and has good protecting action on the liver, the kidney, the pancreas and the intestinal mucosa.

The invention relates to a metal-organic framework-based drug carrier and a preparation method and application thereof to an oral drug carrier. According to the preparation method, MOFs with relatively good stability are synthesized by using a solvothermal method; 5-FU is loaded into the MOFs through a solvent evaporation method; and the outer surfaces of the MOFs are wrapped with chitosan to obtain CS&MOFs@5-FU. The prepared CS&MOFs@5-FU can increase the stability of the MOFs in an acid environment, meanwhile, the chitosan enhances adhesion behaviors to mucus through interacting with a non-covalent bond of a mucus chain to play a certain sustained-release role, the permeability of intestinal mucosa can be improved and the oral bioavailability of drugs can be improved. In addition, the chitosan also has a hole sealing effect and avoids leakage of a large number of drugs in advance. The feasibility is provided for the MOFs serving as the oral drug carrier.